Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
When, if ever, would you consider using encorafenib/binimetinib or vemurafenib/cobimetinib instead of dabrafenib/trametinib for adjuvant treatment of BRAF mutated melanoma?
Related Questions
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
How would you manage a cardiac metastasis from Merkel cell carcinoma?
What is the role of adrenalectomy in managing isolated recurrence of stage IIIc melanoma, occurring 2 years after the original diagnosis, in a patient who declined adjuvant therapy?
Is narrow-band ultraviolet B (nbUVB) phototherapy contraindicated or recommended with caution in patients with a personal history of melanoma?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
How would you approach a patient with desmoplastic melanoma (pT3N0M0) post resection for adjuvant treatment?
